Shares in Australian biotech CSL broke through the $100 level in early trade.
A short time ago, they were trading at $100.090, up 1.28% on yesterday’s close.
The market had been expecting the Commonwealth Bank to be the first to crack the $100 a share barrier earlier this year.
However, the banks have been marked down by investors after a series of flat earnings results. The Commonwealth is trading at $87.94 today.
CSL hit $100 a share once before, in 2007 before its split the stock.
The blood products group is creating the world’s second largest flu vaccine business by buying a subsidiary of Swiss pharmaceutical multinational Novartis for US $275 million (AUD 312 million).